UCB SA 2015 AR2
The report highlights UCB's financial and sustainability performance for the fiscal year 2015, marking its entry into a growth phase driven by its core biopharmaceutical products. The company successfully implemented its Patient Value Strategy, focusing on severe neurological and immunological diseases while expanding its global reach to serve over 1.8 million patients. Key achievements include the approval of Briviact in Europe and the U.S., and positive Phase 3 results for romosozumab in osteoporosis. On the environmental front, UCB reduced its overall Scope 1 and Scope 2 CO2 emissions by 1% and achieved a 95% waste recovery rate. Additionally, the company advanced several CSR initiatives to improve epilepsy care and education in resource-poor countries.
Company: UCB SA
Sector: Health Care
Country: Belgium
Year: 2015
Type: AR2
Pages: 194
UCB SA
Annual Report
The report highlights UCB's financial and sustainability performance for the fiscal year 2015, marking its entry into a growth phase driven by its core biopharmaceutical products. The company successfully implemented its Patient Value Strategy, focusing on severe neurological and immunological diseases while expanding its global reach to serve over 1.8 million patients. Key achievements include the approval of Briviact in Europe and the U.S., and positive Phase 3 results for romosozumab in osteoporosis. On the environmental front, UCB reduced its overall Scope 1 and Scope 2 CO2 emissions by 1% and achieved a 95% waste recovery rate. Additionally, the company advanced several CSR initiatives to improve epilepsy care and education in resource-poor countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees